He will serve as head of the compensation committee.
Barberich founded Sepracor Inc. (NASDAQ: SEPR), a research-based pharmaceutical company, and served as chairman and chief executive officer for over 20 years.
Under his leadership, Sepracor commercialized and partnered several products, including Allegra, Brovana, Clarinex, Lunesta and Xopenex. Before founding Sepracor, Barberich was a senior executive at Millipore Corp.
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialisation of therapies for glaucoma and other eye diseases.
The company's lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development.
Trabodenoson was developed in Inotek's laboratories and is designed to restore the eye's natural pressure control mechanism.
Additionally, the company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases.
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial